What is Kyprolis?
Kyprolis, also known as carfilzomib, is a next generation proteasome inhibitor in the same drug class as Velcade.
The MMRF and it’s affiliate organization, the Multiple Myeloma Research Consortium (MMRC), played an integral role in the development of Kyprolis over the past 6 years. The MMRC provided clinical trial support and resources, including driving patient enrollment to the study which lead to the approval of Kyprolis. Download Kyprolis brochure.